News Shire plans filing for HAE drug after phase 3 success Lanadelumab could revolutionise treatment of swelling disease.
News CEO Meek looks to boost Ipsen with drug acquisitions Could French biotech snap up remaining rights to pancreatic cancer drug?
News Novartis takes option on NASH drug from Conatus Swiss pharma takes option on FXR agonist emricasan.
News PatientsLikeMe and Shire to co-develop rare disease patient ... Data from the new platform will help inform rare disease drug development.
News Novartis takes aim at Shire and Allergan with dry-eye drug Swiss company takes option on Lubris' ECF843.
News Alexion appoints former Baxalta chief Hantson as CEO Former AZ chief David Brennan expected to take over as chairman in May.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
